Nancy Zeleznik-Le
  • Professor
  • Hematology/Oncology

FAK Mediates a Compensatory Survival Signal Parallel to PI3K-AKT in PTEN-Null T-ALL CellsYou,D.; Xin,J.; Volk,A.; Wei,W.; Schmidt,R.; Scurti,G.; Nand,S.; Breuer,E. K.; Kuo,P. C.; Breslin,P.; Kini,A. R.; Nishimura,M. I.; Zeleznik-Le,N. J.; Zhang,J.Cell reports 2015 ;10(12):2055-2068

Degree of Recruitment of DOT1L to MLL-AF9 Defines Level of H3K79 Di- and Tri-methylation on Target Genes and Transformation PotentialKuntimaddi,A.; Achille,N. J.; Thorpe,J.; Lokken,A. A.; Singh,R.; Hemenway,C. S.; Adli,M.; Zeleznik-Le,N. J.; Bushweller,J. H.Cell reports 2015 ;11(5):808-820

FAK is required for c-Met/beta-catenin-driven hepatocarcinogenesisShang,N.; Arteaga,M.; Zaidi,A.; Stauffer,J.; Cotler,S. J.; Zeleznik-Le,N. J.; Zhang,J.; Qiu,W.Hepatology (Baltimore, Md.) 2015 ;61(1):214-226

WEE1 is a validated target of the microRNA miR-17-92 cluster in leukemiaBrockway,S.; Zeleznik-Le,N. J.Cancer genetics 2015 ; ( ):

Importance of a specific amino acid pairing for murine MLL leukemias driven by MLLT1/3 or AFF1/4Lokken,A. A.; Achille,N. J.; Chang,M. J.; Lin,J. J.; Kuntimaddi,A.; Leach,B. I.; Malik,B.; Nesbit,J. B.; Zhang,S.; Bushweller,J. H.; Zeleznik-Le,N. J.; Hemenway,C. S.Leukemia research 2014 ; ( ):

miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemiaLi,Z.; Huang,H.; Chen,P.; He,M.; Li,Y.; Arnovitz,S.; Jiang,X.; He,C.; Hyjek,E.; Zhang,J.; Zhang,Z.; Elkahloun,A.; Cao,D.; Shen,C.; Wunderlich,M.; Wang,Y.; Neilly,M. B.; Jin,J.; Wei,M.; Lu,J.; Valk,P. J.; Delwel,R.; Lowenberg,B.; Le Beau,M. M.; Vardiman,J.; Mulloy,J. C.; Zeleznik-Le,N. J.; Liu,P. P.; Zhang,J.; Chen,J.Nature communications 2012 ;3( ):688

Breaking the LSD1/KDM1A addiction: therapeutic targeting of the epigenetic modifier in AMLLokken,A. A.; Zeleznik-Le,N. J.CANCER CELL 2012 ;21(4):451-453

Overexpression of Foxn1 attenuates age-associated thymic involution and prevents the expansion of peripheral CD4 memory T cells.Zook,E. C.; Krishack,P. A.; Zhang,S.; Zeleznik-Le,N. J.; Firulli,A. B.; Witte,P. L.; Le,P. T.Blood 2011 ;118(22):5723-5731

Aberrant overexpression and function of the miR-17-92 cluster in MLL-rearranged acute leukemiaMi,S.; Li,Z.; Chen,P.; He,C.; Cao,D.; Elkahloun,A.; Lu,J.; Pelloso,L. A.; Wunderlich,M.; Huang,H.; Luo,R. T.; Sun,M.; He,M.; Neilly,M. B.; Zeleznik-Le,N. J.; Thirman,M. J.; Mulloy,J. C.; Liu,P. P.; Rowley,J. D.; Chen,J.Proceedings of the National Academy of Sciences of the United States of America 2010 ;107(8):3710-3715

MicroRNAs in leukemias: emerging diagnostic tools and therapeutic targetsMian,Y. A.; Zeleznik-Le,N. J.Current Drug Targets 2010 ;11(7):801-811

Glycogen synthase kinase-3 and leukemia: restoring the balanceBirch,N. W.; Zeleznik-Le,N. J.CANCER CELL 2010 ;17(6):529-531

Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenesChang,M. J.; Wu,H.; Achille,N. J.; Reisenauer,M. R.; Chou,C. W.; Zeleznik-Le,N. J.; Hemenway,C. S.; Zhang,W.Cancer research 2010 ;70(24):10234-10242

Structure of the MLL CXXC domain-DNA complex and its functional role in MLL-AF9 leukemiaCierpicki,T.; Risner,L. E.; Grembecka,J.; Lukasik,S. M.; Popovic,R.; Omonkowska,M.; Shultis,D. D.; Zeleznik-Le,N. J.; Bushweller,J. H.Nature structural & molecular biology 2010 ;17(1):62-68

Regulation of mir-196b by MLL and its overexpression by MLL fusions contributes to immortalization.Popovic,R.; Riesbeck,L. E.; Velu,C. S.; Chaubey,A.; Zhang,J.; Achille,N. J.; Erfurth,F. E.; Eaton,K.; Lu,J.; Grimes,H. L.; Chen,J.; Rowley,J. D.; Zeleznik-Le,N. J.Blood 2009 ;113(14):3314-3322

Transcriptional complexity of the HOXA9 locusPopovic,R.; Erfurth,F.; Zeleznik-Le,N.Blood cells, molecules & diseases 2008 ;40(2):156-159

Loss of MLL PHD finger 3 is necessary for MLL-ENL-induced hematopoietic stem cell immortalization.Chen,J.; Santillan,D. A.; Koonce,M.; Wei,W.; Luo,R.; Thirman,M. J.; Zeleznik-Le,N. J.; Diaz,M. O.Cancer research 2008 ;68(15):6199-6207

MLL protects CpG clusters from methylation within the Hoxa9 gene, maintaining transcript expression.Erfurth,F. E.; Popovic,R.; Grembecka,J.; Cierpicki,T.; Theisler,C.; Xia,Z. B.; Stuart,T.; Diaz,M. O.; Bushweller,J. H.; Zeleznik-Le,N. J.Proceedings of the National Academy of Sciences of the United States of America 2008 ;105(21):7517-7522

Repression of the PDCD2 gene by BCL6 and the implications for the pathogenesis of human B and T cell lymphomasBaron,B. W.; Zeleznik-Le,N.; Baron,M. J.; Theisler,C.; Huo,D.; Krasowski,M. D.; Thirman,M. J.; Baron,R. M.; Baron,J. M.Proceedings of the National Academy of Sciences of the United States of America 2007 ;104(18):7449-7454

Bromodomain and histone acetyltransferase domain specificities control mixed lineage leukemia phenotype.Santillan,D. A.; Theisler,C. M.; Ryan,A. S.; Popovic,R.; Stuart,T.; Zhou,M. M.; Alkan,S.; Zeleznik-Le,N. J.Cancer research 2006 ;66(20):10032-10039

The MLL fusion gene, MLL-AF4, regulates cyclin-dependent kinase inhibitor CDKN1B (p27kip1) expression.Xia,Z. B.; Popovic,R.; Chen,J.; Theisler,C.; Stuart,T.; Santillan,D. A.; Erfurth,F.; Diaz,M. O.; Zeleznik-Le,N. J.Proceedings of the National Academy of Sciences of the United States of America 2005 ;102(39):14028-14033

MLL: how complex does it get?Popovic,R.; Zeleznik-Le,N. J.Journal of cellular biochemistry 2005 ;95(2):234-242

Structural mechanism of the bromodomain of the coactivator CBP in p53 transcriptional activationMujtaba,S.; He,Y.; Zeng,L.; Yan,S.; Plotnikova,O.; Sachchidanand; Sanchez,R.; Zeleznik-Le,N. J.; Ronai,Z.; Zhou,M. M.Molecular cell 2004 ;13(2):251-263

Characterization of genomic breakpoints in MLL and CBP in leukemia patients with t(11;16)Zhang,Y.; Zeleznik-Le,N.; Emmanuel,N.; Jayathilaka,N.; Chen,J.; Strissel,P.; Strick,R.; Li,L.; Neilly,M. B.; Taki,T.; Hayashi,Y.; Kaneko,Y.; Schlegelberger,B.; Rowley,J. D.Genes, chromosomes & cancer 2004 ;41(3):257-265

Cryptic ins(2;11) with clonal evolution showing amplification of 11q23-q25 either on hsr(11) or on dmin, in a patient with AML-M2Vazquez,I.; Lahortiga,I.; Agirre,X.; Larrayoz,M. J.; Vizmanos,J. L.; Ardanaz,M. T.; Zeleznik-Le,N. J.; Calasanz,M. J.; Odero,M. D.Leukemia 2004 ;18(12):2041-2044

Polymorphisms in the MLL breakpoint cluster region (BCR)Echlin-Bell,D. R.; Smith,L. L.; Li,L.; Strissel,P. L.; Strick,R.; Gupta,V.; Banerjee,J.; Larson,R.; Relling,M. V.; Raimondi,S. C.; Hayashi,Y.; Taki,T.; Zeleznik-Le,N.; Rowley,J. D.Human genetics 2003 ;113(1):80-91

A t(11;15) fuses MLL to two different genes, AF15q14 and a novel gene MPFYVE on chromosome 15Chinwalla,V.; Chien,A.; Odero,M.; Neilly,M. B.; Zeleznik-Le,N. J.; Rowley,J. D.Oncogene 2003 ;22(9):1400-1410

Characterization of the MLL partner gene AF15q14 involved in t(11;15)(q23;q14)Kuefer,M. U.; Chinwalla,V.; Zeleznik-Le,N. J.; Behm,F. G.; Naeve,C. W.; Rakestraw,K. M.; Mukatira,S. T.; Raimondi,S. C.; Morris,S. W.Oncogene 2003 ;22(9):1418-1424

MLL repression domain interacts with histone deacetylases, the polycomb group proteins HPC2 and BMI-1, and the corepressor C-terminal-binding protein.Xia,Z. B.; Anderson,M.; Diaz,M. O.; Zeleznik-Le,N. J.Proceedings of the National Academy of Sciences of the United States of America 2003 ;100(14):8342-8347

A novel gene, MDS2, is fused to ETV6/TEL in a t(1;12)(p36.1;p13) in a patient with myelodysplastic syndromeOdero,M. D.; Vizmanos,J. L.; Roman,J. P.; Lahortiga,I.; Panizo,C.; Calasanz,M. J.; Zeleznik-Le,N. J.; Rowley,J. D.; Novo,F. J.Genes, chromosomes & cancer 2002 ;35(1):11-19

Mammalian septins nomenclatureMacara,I. G.; Baldarelli,R.; Field,C. M.; Glotzer,M.; Hayashi,Y.; Hsu,S. C.; Kennedy,M. B.; Kinoshita,M.; Longtine,M.; Low,C.; Maltais,L. J.; McKenzie,L.; Mitchison,T. J.; Nishikawa,T.; Noda,M.; Petty,E. M.; Peifer,M.; Pringle,J. R.; Robinson,P. J.; Roth,D.; Russell,S. E.; Stuhlmann,H.; Tanaka,M.; Tanaka,T.; Trimble,W. S.; Ware,J.; Zeleznik-Le,N. J.; Zieger,B.Molecular biology of the cell 2002 ;13(12):4111-4113

The human programmed cell death-2 (PDCD2) gene is a target of BCL6 repression: implications for a role of BCL6 in the down-regulation of apoptosisBaron,B. W.; Anastasi,J.; Thirman,M. J.; Furukawa,Y.; Fears,S.; Kim,D. C.; Simone,F.; Birkenbach,M.; Montag,A.; Sadhu,A.; Zeleznik-Le,N.; McKeithan,T. W.Proceedings of the National Academy of Sciences of the United States of America 2002 ;99(5):2860-2865

Retroviral transduction model of mixed lineage leukemia fused to CREB binding proteinLiedman,D.; Zeleznik-Le,N.Current opinion in hematology 2001 ;8(4):218-223

The partial nontandem duplication of the MLL (ALL1) gene is a novel rearrangement that generates three distinct fusion transcripts in B-cell acute lymphoblastic leukemiaWhitman,S. P.; Strout,M. P.; Marcucci,G.; Freud,A. G.; Culley,L. L.; Zeleznik-Le,N. J.; Mrozek,K.; Theil,K. S.; Kees,U. R.; Bloomfield,C. D.; Caligiuri,M. A.Cancer research 2001 ;61(1):59-63

Cytogenetic and molecular analysis of the acute monocytic leukemia cell line THP-1 with an MLL-AF9 translocationOdero,M. D.; Zeleznik-Le,N. J.; Chinwalla,V.; Rowley,J. D.Genes, chromosomes & cancer 2000 ;29(4):333-338

DNA structural properties of AF9 are similar to MLL and could act as recombination hot spots resulting in MLL/AF9 translocations and leukemogenesisStrissel,P. L.; Strick,R.; Tomek,R. J.; Roe,B. A.; Rowley,J. D.; Zeleznik-Le,N. J.Human molecular genetics 2000 ;9(11):1671-1679

Chromatin-related properties of CBP fused to MLL generate a myelodysplastic-like syndrome that evolves into myeloid leukemiaLavau,C.; Du,C.; Thirman,M.; Zeleznik-Le,N.The EMBO journal 2000 ;19(17):4655-4664